상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Current pharmacotherapies for atherosclerotic cardiovascular diseases

Authors 

Jong Gil ParkG T Oh

Publisher 

Pharmaceutical Society of Korea

Issue Date 

2019

Citation 

Archives of Pharmacal Research

Keywords 

Atherosclerotic cardiovascular diseases (ASCVD)Pharmaceutical therapiesLipid-lowering

Abstract 

Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1b (IL-1b) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.

URI 

https://doi.org/10.1007/s12272-019-01116-1

ISSN 

0253-6269

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2019-07-10


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)